Home/Pipeline/Cannabics® PRST-33

Cannabics® PRST-33

Prostate Cancer

PreclinicalActive

Key Facts

Indication

Prostate Cancer

Phase

Preclinical

Status

Active

Company

CNBX Pharmaceuticals

About CNBX Pharmaceuticals

CNBX Pharmaceuticals is a clinical-stage biotech company developing a pipeline of cannabinoid-based drug candidates for cancer and neuropsychiatric disorders. Its core asset, RCC-33, is positioned as a first-in-class candidate for colorectal cancer, currently in late preclinical stages preparing for an IND. The company utilizes an in-house drug discovery platform centered on high-throughput screening of cannabinoid formulations against various cancer types. Leadership combines business acumen with scientific and clinical expertise, supported by a notable advisory board in oncology.

View full company profile

Therapeutic Areas

Oncology Neuropsychiatry Gastroenterology

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active
Mitomic™ Test for Prostate Cancer	MDNA Life Sciences	Development/Validation	Active
Immunomodulator Platform	OmniCyte	Research	Active
Prostate cancer 'super test'	EDX Medical	Development	Active
PSMA-Dex	DexTech Medical	Pre-clinical	Active